Rubió News

Laboratorios Rubió announces that it has capacity to triple its production of hydroxychloroquine

March 26, 2020 (EFE)

Laboratorios Rubió, a Spanish pharmaceutical company that manufactures and markets Dolquine, a hydroxychloroquine-based medicine that is being used in the treatment of COVID-19, has announced that it has the capacity to triple its production to respond to the needs of the coronavirus.

The laboratory has reported in a statement that it has been made available to the Spanish Agency for Medicines and Health Products (Aemps) to be able to supply the drug based on its current production capacities.

See news in Spanish


XLIV National Congress of the Spanish Society of Rheumatology (SER)

May 2018 – Laboratorios Rubió has had a notorious presence at the XLIV National Congress of the Spanish Society of Rheumatology (SER), which enrolled about 1,200 professionals in the world of rheumatic diseases, and which took place from May 23 to 25 in A Coruña.

The National Congress is the maximum scientific event organized by this company, so we consider it essential our active participation through the presence in the commercial area of ​​a stand that has not gone unnoticed, and that has allowed to generate demand for information about our entire portfolio in this area. Under the motto TODOS SomosReumatologia and using the back of Rubió within this therapeutic area we have managed to outline a map that defines Rubió’s career very well under the slogan Life is Adventure, discover Rubió’s Adventure.

From Laboratorios Rubió we have also participated in providing scientific documentation in the congressman’s portfolio, which will allow us to better understand Rubió’s vademecum in this therapeutic area.

It is worth noting two important issues of this XLIV National Congress of the SER, the first and as a novelty compared to previous editions is that for the first time Laboratorios Rubió has been present in the commercial exhibition area and not only that, but it has been premiered with a novel and differential theme. The second issue, and no less important, is that this participation has allowed us to make an attractive activity on the stand that has generated great interest in specialists, has facilitated communication with attendees and has been a great opportunity for Rubió at two levels : at the company level, giving visibility to our Rubió brand and to the fact of the 50th Anniversary of the Laboratory, and at a professional level, sharing Rubió’s experience in rheumatology, with a portfolio of first-line treatment products with great experience in the market .

The entire team of SomosReumatologia de Laboratorios Rubió would like to thank you for the welcome and support you have given us. It has been a unique experience that we hope to repeat again very soon.

Reindustrialization and Promotion of Industrial Competitiveness Program

November 2017.- Laboratorios Rubió is carrying out the plan to improve traceability in its production processes through financing from the Ministry of Industry, Commerce and Tourism, within the Program of Reindustrialization and Promotion of Industrial Competitiveness.


XXII National Congress of the SEIOMM

October 2017Elche (Alicante) hosted the XXII National Congress of the SEIOMM (Spanish Society of Bone Research and Mineral Metabolism) from October 25 to October 27 at the Ciutat d’Elx Congress Center, where around 400 professionals from the bone world. The National Congress is the maximum scientific event organized by SEIOMM, so we consider it essential our active participation through the presence in the commercial area with a stand, which has not gone unnoticed, and that has allowed to generate demand for information about our flagship product, an alendronate in oral solution, for the treatment of postmenopausal osteoporosis.

We have also participated in providing scientific documentation in the congressman’s portfolio, documentation on our product and on the online course promoted and endorsed by SEIOMM and which has been declared of scientific interest by the SER and which, of course, sponsors Rubió: Problems and Solutions in the approach to Osteoporosis ( . A course whose objective is to update the clinical practice of the approach to osteoporosis, the clinical problems associated with the disease and the therapeutic solutions.

Two important issues of this XXII National Congress of the SEIOMM, the first and as a novelty with respect to previous editions, is that this year they had a Pre-Congress course on bone metabolism update, in which they reviewed the novelties in the different topics of interest. A course that has been addressed to all professionals with an interest in bone. The second and not least is that it has achieved an authentic record of attendees, which has led to the fact that, from the point of view of attendance, the congress held in Elche was the best congress in the history of the SEIOMM.


XI Update Day in Child and Adolescent Psychiatry

June 2017Pamplona hosted the XI Update Day in Child and Adolescent Psychiatry last June 23 in the auditorium of Civican, where more than 60 experts in Psychiatry and Psychology of children and adolescents met; Mainly psychiatrists, clinical psychologists, pediatricians, primary care physicians, as well as social workers, education specialists, school counselors and institutes.

Leading experts from the United Kingdom, Madrid and Navarre, under the title “Etiologic factors and new management options for ADHD and other neurodevelopmental disorders”, presented the main novelties and key points in the treatment and intervention of Attention Deficit Hyperactivity Disorder (ADHD) and other neurodevelopmental disorders in children.

An inescapable appointment of high scientific level for all the professionals of the specialty; A great opportunity for Laboratorios Rubió, involved in ADHD since 1983 to collaborate and show their professionalism and commitment to improving the approach to treatment of these young people, and thus continue to be trusted with all the trust offered by so many families and specialists.


2nd Agora Wellness Congress

June 2017 – On 21 and 22 June, the National Institute of Occupational Health and Safety hosted the 2nd Agora Bienestar Congress, an itinerant congress that offers a global vision of solutions and trends of well-being based on the exchange of knowledge and experiences , Both from the personal perspective (body and mind) and business (environment).
Laboratorios Rubió collaborated in a table on medical innovations in the service of the well-being before more than 200 doctors and other professionals of the world of the health in the company. It explained the great importance of knowing our cardiovascular well-being to prevent the occurrence of cardiovascular diseases, and how the Advanced Test of Lipoproteins allows to detect the appearance of these diseases with greater precision and anticipation.

Day of update in dyslipemias: advances in diagnosis, treatment and application to the work environment

June 2017 – The Ministry of the Presidency and for the Territorial Administrations, in collaboration with the company Suministros Hospitalarios Clinifarma and with Laboratorios Rubió, held on 22 June a Day of updating in dislipemias in the dependencies of the Moncloa. About 100 doctors who are experts in cardiovascular risk were interested in the latest changes in the sector.

The day was moderated by Dr. Gregorio Gil López, head of the medical cabinet in the Ministry of the Presidency; and counted as speakers with Dr. José Antonio García Donaire, Nephrologist researcher of the Biomedical Foundation of the San Carlos Clinical Hospital; and with Dr. Vicente Pallarés Carratalá, doctor specialized in family and community medicine. After an update on the systems for diagnosis, prevention and treatment of dyslipidemias, the LIPOSCALE test was presented as a new Advanced Test of Lipoproteins capable of improving the evaluation of the cardiovascular risk of patients.

34th National Edition Training SEGO

June 2017 – This year, the Spanish Society of Gynecology and Obstetrics (SEGO) organized the 34th edition of its biannual congress at the Palacio de Congresos de Oviedo, from 12 to 16 June, where it deployed an extensive scientific program of conferences, discussion tables, workshops And symposia that addressed current issues in the field of gynecology and obstetrics.

In this 34º National Edition Training SEGO gathered about 2,300 specialists throughout the week. The Congress had a large commercial exhibition area with a total of approximately 71 companies / laboratories, including Laboratorios Rubió, which presented to the attendees the portfolio of the area of ​​gynecology and obstetrics: two diagnostic tests, one for diagnosis of rupture Prematurity of membranes “Actim PROM” and the other for diagnosis of premature birth “Actim PARTUS”, Cicatridina for the tonicity, trophism and elasticity of vaginal and rectal tissue and, finally, our launch this year for the treatment of Postmenopausal osteoporosis.

It is worth mentioning the interest of the specialists for our products, which led to generate a significant traffic in the area of ​​the stand.

Once again, we join the congress bets for innovation, participation, updating and excellence of the scientific debate.

XIX Congresss SEOR

June 2017 – Santander hosted the XIX Congress of the Spanish Society of Radiation Oncology (SEOR) from June 8 to 10 in its Palace of Exhibitions and Congresses, where about 1,000 professionals from this medical specialty were found in Spain and in industry Pharmaceutical, to know the latest details in technological innovation in the clinical practice of radiotherapy oncology, and on patient care. The purpose of the congress was to publicize the processes of improvement in the quality of care in this specialty and encourage the participation of professionals in outreach projects and clinical management processes.
An important appointment that Laboratorios Rubió could not miss, given his portfolio of products based on hyaluronic acid intended to improve the quality of life of cancer patients. As a laboratory involved in the therapeutic area of ​​radiation oncology, our products were named during the scientific presentations and, in addition, we participate actively in the area of ​​trade exhibition.

3rd Day Advanced Lipidology

May 2017 – Cardiovascular diseases continue to be one of the main health problems in developed countries. In Spain they are responsible for 29.66% of all deaths, according to the latest data from the National Institute of Statistics (2014). These data indicate the need for independent and quality forums in which, from a practical perspective, they can improve the daily clinical practice of the specialists involved and facilitate the management of the disease, as well as the prevention of complications.

For these reasons, as part of our commitment to continuing medical education for the improvement of public health, Laboratorios Rubió, part of the Foundation for Research and Prevention of Cardiovascular Diseases (FIPEC), has been organizing an advanced program of Update on treatments and knowledge in lipidology. These days have resulted in a pragmatic instrument of high quality for the continuous improvement of daily clinical practice. The third day took place the weekend of May 19 to 20 at the Parador de la Granja de Segovia, housing a total of 30 specialists who attended the presentations of 7 reference specialists to analyze the situation of patients with dyslipemia And assess existing treatments in the market.

55th SERMEF Congress

May 2017 – Every year the Spanish Society of Rehabilitation and Physical Medicine (SERMEF) meets in a city of Spain to celebrate its national congress. On this occasion, the host city was Pamplona hosting more than 600 experts in Physical Medicine and Rehabilitation from 15 to 20 May at the Palace of Congresses Baluarte in its fifty-fifth edition.

The meeting, with an important collaboration of Laboratorios Rubió as sponsor, counted on the participation of national and international referents in the field of rehabilitation and physical medicine, who addressed, among other topics, the advances in rehabilitation; (Neuro-rehabilitation, rehabilitation for children, geriatric, cardiac, oncological …) and where the commitment to management, interventionism and innovation was also reflected through the new assessment and therapeutic technologies, dealing with novelties in biomechanical evaluation systems, Telerrehabilitation, robotics and interventional ultrasound.


11th DIATROS Course

April 2017 – Laboratorios Rubió, always advocating the dissemination of scientific knowledge and advances in the health care of women, showed its support through sponsorship in the eleventh edition of the DIATROS Course, a new edition in which New initiatives and challenges. On this occasion, under the title Care for Women’s Health Initiatives and Challenges, DIATROS offered the opportunity to learn about the latest scientific and clinical advances in order to improve daily clinical practice. In addition, this year had its own APP for Android and iOS facilitating a networking service among attendees.

This multidisciplinary meeting that took place at the AXA Auditorium in Barcelona from the 26th to the 28th of April hosted more than 500 professionals of national scope, who were able to share experience and attend the lectures given by opinion leaders of great prestige at national level And international. On this occasion, the conference sponsored by Laboratorios Rubió was led by Dr. M. Lilue Bajares, Head of the Obstetrics Unit of the Palacios Institute of Health and Women’s Medicine (Madrid), which addressed the role of hyaluronic acid in Tissue regeneration and its application in cervical-vaginal repair in patients undergoing radiotherapy.

18th ASESA Congress

April 2017 – The 18th Congress of the Spanish Association of Andrology, Sexual and Reproductive Medicine was held in Cartagena, from April 20 to 22, 2017.

The work program has included plenary and training sessions, with oral communications and posters, which addressed topical issues related to the professional and experimental areas of the participants.

This congress, celebrated biannually, has counted this year with more than 160 registered, coming from all the national territory.

Laboratorios Rubió was one of the sponsors of the congress, sponsoring a Testosterone Training Course, with first level speakers such as Dr. Manuel Mas García, Professor of Physiology and Director of the Center for Sexological Studies (CESEX) at the University of La Laguna ; Dr. Ana María Segura Paños, andrologist at the Vistahermosa Clinic and in the andrology unit of the General University Hospital of Alicante; And Dr. Josep Torremadé Barrera responsible for the Andrology Unit of the Hospital of Bellvitge and director of the Institute of Andrology and Male Sexuality (IXMA) of the QuironSalud Group.

On-Line Clinical Case Contest with ADHD

Laboratorios Rubió endorsed by the Spanish Society of Pediatric Neurology has launched the first edition of the On-Line Contest of Clinical Cases on the pharmacological approach of patients with ADHD.

This initiative intends to emphasize the need to improve the management and treatment of these patients, as well as to recognize the involvement and scientific contribution of specialist physicians experienced in this neurodevelopmental disorder and affecting pediatric patients.

To this end, Laboratorios Rubió proposes a collection of documented clinical cases that describe the evolution of patients diagnosed with ADHD, whose therapeutic selection was prior to the end of 2016. Those clinical cases most representative of the collection will be published in a monograph that will contribute to The dissemination of knowledge and training of the health professional, in addition, the winners and finalists will receive an economic compensation stipulated in the rules of the contest

The scientific committee responsible for the evaluation of the cases, will be formed by Dr. in Psychiatry J. Cantó Diez, (Children’s Mental Health Unit of the General University Hospital of Alacante Conselleria de Sanitat Universal – Generalitat Valenciana) and by Dr. Pediatrics Manuel A. Fernández Fernández (Andalusian Institute of Pediatric Neurology).

The period of validity of this contest is, since the publication of the present bases on the website , until May 31, 2017, being able to extend the term in certain circumstances.

ADHD Update Symposium

March 2017 – The Adana Foundation triennially organizes a symposium to update knowledge and information on the latest advances in ADHD. Through the same it is also intended to promote debate and reflection for the improvement of diagnosis and treatment, promoting prevention for the improvement of the evolution of the disorder and its comorbidities.

The V Symposium, aimed mainly at physicians, pediatricians, psychiatrists, neuropediatricians, family doctors, neurologists, psychologists and other health, education and social professionals, took place on March 10 and 11, 2017 in Auditorium of the University Ramón Llull, Blanquerna (Faculty of Psychology).

XIX International Congress on Neurodevelopmental Disorders

March 2017 – On March 3 and 4, 2017, the XIX International Congress on Neurodevelopmental Disorders was held in Valencia, organized by Dr. Fernando Mulas, Neuropediatrician and Director of INVANEP.

Laboratorios Rubió has collaborated and participated actively in this interdisciplinary conference where neuropediatricians, children’s psychiatrists, psychologists, psychopedagogues, speech therapists, pedagogues and therapists are cited for their continuing education by renowned national and international experts and speakers.

In this issue, interesting topics such as Autism Spectrum Disorder (TEA), neurodevelopment and learning difficulties, sensory and language processing disorders, Attention Deficit Hyperactivity Disorder (ADHD) With the participation of Prof. Samuele Cortese (Southamton, England), a specialist in ADHD with an upward projection for its international scientific recognition, who has held the inaugural and closing conference.

World knee day

March 2017 – The International Society of Nephrology (ISN) and the Foundation for Kidney Federations (NKF) have been encouraging all Nephrology Societies and Renal Disease Associations to celebrate “World Day Of the Kidney “, with slogans differentiated each year, to give greater emphasis to the causes of Chronic Kidney Disease and raise awareness of the general population and also the professionals in the management of a pathology that can affect about 10% of the population.

On the occasion of the celebration of “World Kidney Day” on March 9, under the motto “Kidney disease and obesity: Healthy lifestyle for healthy kidneys”, the Spanish Society of Nephrology in collaboration with ALCER and SEDEN Carry out an awareness campaign for politicians and the general population. To this end, a photocall has been requested on the same day March 9, taking advantage of the fact that there is a plenary session in the Congress of Deputies, where politicians will be invited to photograph themselves by biting an apple in a symbolic way. It has also been requested to hold a press conference, also in the Congress, with the participation of the media assistants and representatives of the S.E.N., ALCER and SEDEN.

In addition, a series of actions will be carried out at national level (cooking workshops and video recording with relevant cooks conveying the message of healthy lifestyle, with the collaboration of ALCER) as well as the production of informative material, in Form of posters with the official logo and slogan proposed by the ISN and IFKF that will be distributed in all nephrology services and SEN partners.

Given the involvement of Laboratorios Rubió with nephrology, we are collaborating in this initiative at institutional level. We attach the link where to consult the different actions that will be carried out this Thursday and where we appear together with the other collaborating entities.

Laboratorios rubió launches soludronate® semanal 70 mg. Oral solution

February 2017– Laboratorios Rubió launches Soludronate® Semanal 70 mg. solución oral, the first and only alendronic acid oral solution for prevention and treatment of osteoporosis, mainly postmenopausal. This ready-to-take formulation facilitates administration and reduces side effects associated with other alendronic acid dosage forms, improving patient adherence to treatment.

Soludronate® Weekly presents viscosifying agents that optimize the transport through the digestive system and allow a faster access of the treatment to the place of absorption, contributing to a better gastric tolerance, favoring the compliance of the pattern marked by the specialist.

The objective of Rubió Laboratories is to make known this treatment option through a medical visit to specialists who treat patients with osteoporosis diagnosis, mainly postmenopausal.

Laboratorios rubió launch picasum 0,075% crema to the market

January 2017– Laboratorios Rubió just launched Picasum 0,075% crema, a capsaicin indicated for the moderate to severe Painful Diabetic Neuropathy treatment, in monotherapy or combination therapy.
About 15% of the Spanish population is diabetic and a clear majority of them suffer to some degree of neuropathy. Laboratorios Rubió is presenting this treatment option to all those specialists treating the diabetic patients: endocrinologists, pain units and primary care, to allow the to treat those patients improving the quality of their lives. Picasum 0,075% crema available in tubes of 30gr. or 50gr

Collaboration with ii curso de andrología de la seen

October 2016.– The II Andrology Course, promoted by the Spanish Society of Endocrinology and Nutrition (SEEN), has been supported and sponsored by Rubió Laboratories, a company always committed to initiatives that contribute to knowledge sharing. The course has been well received by professionals and has had 17 Spanish and European speakers of recognized prestige, who have addressed subjects from different disciplines, such as endocrinology, urology, pediatrics and biology.

In this course, held in Madrid, the following thematic blocks have been addressed: testicular pathophysiology, management and care of the patient with adult hypogonadism, sexual development and function, male infertility and systemic diseases and reproductive dysfunction, as well as several clinical cases. To conclude, the course has been closed with a look to the future thanks to the presentation ‘Future perspectives of andrology’ by the president of the European Academy of Andrology (AEA), Csilla Krausz.

58th congress of the spanish society of endocrinology

October 2016– The Spanish Society of Endocrinology and Nutrition (SEEN) celebrated this year its 58th Spanish National Congress in the city of Malaga which has been attended by about 2000 endocrine across the country. The Congress, which has presented an interesting program of high scientific level, has revealed many relevant aspects of these specialist’s activity.

Laboratorios Rubió is actively working with KOLs and many members of this scientific society, since the endocrines prescribe some of its products, as they are the appropriate therapy for their patients.

Laboratorios Rubió, always looking to create areas for discussion and exchange of knowledge, has sponsored a presentation on the importance of testosterone: ‘The testicle, a key organ in the “cross-talk” between bone, muscle and cardiovascular health’, which has been given by Dr. Guillem Cuatrecasas, Endocrinologist of Teknon Medical Center in Barcelona investigator of several international studies.

Laboratorios rubió collaborate with la federación española del ictus to raise awareness about the gravity of the stroke disease

October 2016.- Laboratorios Rubió, committed to health and quality of life, collaborates with FEDERACIÓN ESPAÑOLA DEL ICTUS (FEI) to raise awareness about the consequences of the stroke disease and the need to prevent it.

For the World Stroke Day, the FEI has organized a traveling photo exhibition called “Historias de un Ictus” (Stroke Stories) which will visit several Spanish cities, from this month until the end of the year, with Laboratorios Rubió support.

The exhibition deals with the stories of four people of different ages and backgrounds, who have suffered a stroke, not from the perspective of the disease but through daily acts of personal growth. The incidence of this disease reflects the severity of this problem, since it is known that 1 in 6 people will suffer a stroke over their lifetime.

The specialists claim that the new test of determination of Lipoproteínas is already used in clinical practice

July 2016 -The specialists value the use of a technique called LIPOSCALE that analyzes the size and number of lipoproteins in cardiovascular screening.

“Until now, we did not have in the clinic of any tool, of any test or advanced test of determination of lipoproteínas; But recently a technology has been developed in Spain based on magnetic resonance spectroscopy of two dimensions that allows to analyze, through a relatively simple and exportable procedure to the clinic, the patient’s lipoprotein map, it is to be hoped that it will soon be available to clinicians”, said Dr. Jacinto Fernández Pardo, head of the Arterial Hypertension and Lipids Unit of the General University Hospital Reina Sofía of Murcia, during his speech at a panel on ‘Importance Of the size of lipoproteins in cardiovascular screening: from theory to clinical practice ‘, which took place during the XXIX National Congress of the Spanish Society of Arteriosclerosis (SEA) held in Granada last May.

Launch of new drug, testogel, in an event with medical professionals from different fields

June, 2016. The new drug, Testogel, a hydroalcoholic gel that is colourless and clear, containing 1% testosterone, was launched at an event organised by the Centre of Urology, Andrology and Reproductive Medicine in conjunction with Laboratorios Rubió. The event was attended by professionals from different fields, who were able to see the product’s characteristics first hand.

The aim was to raise the profile of the treatment of hypercholesterolaemia with resins to reduce cholesterol, which is related to the metabolic syndrome of patients with erectile dysfunction. The various professionals had the opportunity to discuss the most pressing topics in the field of urology, andrology, endocrinology and reproductive health.

A new predictive test will allow greater accuracy of cardiovascular risk.

May 2016 – This technology created from the use of nuclear magnetic resonance is called LIPOSCALE and is already being applied in many clinical studies on different pathologies.

A new predictive test “will allow better treatment, better estimation and greater precision of our patients’ cardiovascular risk,” said Dr. Ángel Díaz Rodríguez, coordinator of the Working Group of Lipids of the Spanish Society of Primary Care (SEMERGEN).

Dr. Díaz Rodríguez participated in the Mesa ‘Importance of the size of lipoproteins in the screening of cardiovascular risk: LIPOSCALE’, held in the framework of SEMERGEN Cardiovascular Conferences (Santander, from May 19 to 21, 2016), session in Which was also attended by doctors Nuria Amigó Grau and Vicente Pallarés Carratalá. This technology created from the use of nuclear magnetic resonance is called LIPOSCALE and is already being applied in many clinical studies on different pathologies.

Cystistat, an example for professionals working in radiation oncology

March, 2016 – Laboratorios Rubió, as part of its continuous dedication to research and promotion of scientific inquiry, was a driving force behind the conference “Current state of the prevention and treatment of acute and late toxicity in the pelvis. An original technique for radiation cystitis”, that was presented as part of the 8th Congress on Complementary Therapies in Radiation Oncology. This congress, held at Madrid’s Hospital de la Paz and attended by more than 250 professionals, offers a wide programme of high educational value, led by specialists Ana Mañas and Alejandro de la Torre.

The conference driven by Rubió was led by Dr Luis Olay, head of the prostate division of the radiation oncology service of the Hospital Universitario Central de Asturias (HUCA), who presented a real-life case of a patient undergoing radiation therapy treated with Cystistat, with a very good prognosis and progression. “We used Cystistat because of its molecular weight, efficacy and concentration, which make it the ideal hyaluronic acid for this technique. Not all hyaluronic acids are the same”, he stated in his presentation. The aim of the congress is to bring medical knowledge in radiation therapy up to date, in order to improve the quality of life of cancer patients, reduce the complications they suffer, and treat their long and short-term side effects.

Laboratorios rubió and incliva sign an agreement to jointly promote biomedical research

February, 2016 – Rafael Carmena and Carlos Rubió, General Directors of the INCLIVA Health Research Institute and Laboratorios Rubio respectively, signed a collaborative agreement in June whose aims include research, development, innovation, training and promotion of scientific inquiry in the field of biomedicine.

Both entities are aware of the importance of promoting and strengthening cooperation in technical, scientific, economic and educational aspects of the field, as a tool to spark the development of research and the economy.

Laboratorios rubió invests in biotech company to co-develop a predictive cardiovascular test that is the first of its kind in europe

September, 2014 – Laboratorios Rubió, a family company specialising in treatment solutions for low prevalence diseases, has acquired 30% of the company Biosfer Teslab, a spin-off of the Universidad Rovira i Virgili (URV) and the Institut d’Investigació Sanitària Pere Virgili (IISPV), to drive the development of a predictive test for cardiovascular risk that is the first of its kind in Europe.

As part of its commitment in the field of R&D&i, Rubió will make an initial investment of more than half a million Euros to undertake the final phase of product development and its launch onto the market. The company will hold exclusive rights in the European market, and have preferential rights over the product in the rest of the world. The new product, which will be available on the market in 2016, is an advanced lipoprotein test that allows the size and concentration of particles that transport LDL to be calculated, since these characteristics make it possible to more accurately assess the risk of suffering from cardiovascular problems